SCHEMBL20652947

SCHEMBL20652947

CC(C)n1c(=O)n(CCCO)c(=O)c2c1nc(-c1cc(F)cnc1OCC1CC1)n2Cc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 5/20 0.43
▸ P2RX3 P56373 4/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ USP1 O94782 1/20 0.36
▸ HIF1A Q16665 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ TRPC4 Q9UBN4 1/20 0.36
▸ TRPC5 Q9UL62 1/20 0.36
▸ LMNA P02545 2/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ BRAF P15056 1/20 0.36
▸ PIK3CG P48736 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20652819 0.95 P2RX3 (0.39) ADORA3P2RX3ALDH1A1USP1KCNH2
SCHEMBL20655954 0.92 ADORA3 (0.42) ADORA3P2RX3KDM4EALDH1A1USP1
SCHEMBL20652815 0.90 ADORA3 (0.43) ADORA3P2RX3RAB9AKDM4EALDH1A1
SCHEMBL20652948 0.88 ADORA3 (0.41) ADORA3P2RX3RAB9AKDM4EALDH1A1
SCHEMBL20653072 0.88 ADORA3 (0.42) ADORA3P2RX3RAB9AKDM4EALDH1A1
SCHEMBL20652816 0.88 ADORA3 (0.42) ADORA3P2RX3RAB9AKDM4EALDH1A1
SCHEMBL20652796 0.87 P2RX3 (0.42) P2RX3ALDH1A1HIF1ALMNAMAPK1
SCHEMBL20652731 0.86 PKM (0.40) ADORA3P2RX3USP1KCNH2TRPC4
SCHEMBL20652951 0.86 FFAR4 (0.36) ADORA3P2RX3ALDH1A1USP1KCNH2
SCHEMBL20652756 0.86 P2RX3 (0.39) ADORA3P2RX3KCNH2TRPC4TRPC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3652176-B1 SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INT (DE) 2021-12-15 — — EP disclosed
US-10329292-B2 Substituted xanthine derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-06-25 — — US disclosed
WO-2019011802-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-01-17 — — WO disclosed
US-20190016722-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329292-B2 Substituted xanthine derivatives TRPC5, TRPV1, TRPC4 ADORA3 352/4885P2RX3 21/4885RAB9A 2997/4885
US-20190016722-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES TRPC5, TRPC4, TRPV1 ADORA3 366/4885P2RX3 19/4885RAB9A 2796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback